Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Heron Therapeutics	Supernus Pharmaceuticals	ADC Therapeutics	Aurinia Pharmaceuticals	Amneal Pharmaceuticals
Symbol	NASDAQ:HRTX	NASDAQ:SUPN	NYSE:ADCT	NASDAQ:AUPH	NYSE:AMRX
Price Information
Current Price	$17.56	$29.35	$22.48	$10.00	$5.31
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.7	1.9	1.7	1.5	2.0
Analysis Score	3.4	3.5	3.4	3.4	3.4
Community Score	2.7	3.0	3.7	3.0	2.2
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	1.7	0.8	0.8	0.0
Earnings & Valuation Score	0.6	1.3	0.6	0.0	4.4
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$26.00	$37.50	$49.25	$28.00	$7.00
% Upside from Price Target	48.06% upside	27.77% upside	119.08% upside	180.00% upside	31.83% upside
Trade Information
Market Cap	$1.61 billion	$1.56 billion	$1.55 billion	$1.28 billion	$1.59 billion
Beta	1.52	1.38	N/A	0.87	1.27
Average Volume	1,034,451	579,335	328,156	4,369,125	1,807,015
Sales & Book Value
Annual Revenue	$145.97 million	$392.76 million	$2.34 million	$320,000.00	$1.63 billion
Price / Sales	11.03	3.96	661.83	4,003.78	0.98
Cashflow	N/A	$2.60 per share	N/A	N/A	$1.24 per share
Price / Cash	N/A	11.30	N/A	N/A	4.29
Book Value	$4.48 per share	$11.35 per share	N/A	$2.45 per share	$1.16 per share
Price / Book	3.92	2.59	∞	4.08	4.58
Profitability
Net Income	$-204,750,000.00	$113.06 million	$-116,480,000.00	$-123,850,000.00	$-361,920,000.00
EPS	($2.50)	$2.10	($2.36)	($0.89)	$0.27
Trailing P/E Ratio	N/A	12.18	N/A	N/A	12.95
Forward P/E Ratio	N/A	18.58	N/A	N/A	8.05
P/E Growth	N/A	N/A	N/A	N/A	0.29
Net Margins	-216.18%	27.09%	N/A	-173,992.23%	3.30%
Return on Equity (ROE)	-65.06%	20.02%	N/A	-36.98%	42.02%
Return on Assets (ROA)	-49.14%	9.67%	N/A	-31.06%	3.82%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.53%	0.28%	N/A	8.20%
Current Ratio	3.60%	1.84%	15.55%	17.23%	2.31%
Quick Ratio	3.16%	1.70%	15.55%	16.95%	1.60%
Ownership Information
Institutional Ownership Percentage	99.01%	96.11%	40.88%	51.21%	33.49%
Insider Ownership Percentage	12.85%	6.57%	N/A	N/A	26.32%
Miscellaneous
Employees	223	563	208	294	6,000
Shares Outstanding	91.68 million	53.02 million	68.89 million	128.12 million	299.82 million
Next Earnings Date	5/12/2021 (Estimated)	8/17/2021 (Estimated)	8/17/2021 (Estimated)	8/10/2021 (Estimated)	8/5/2021 (Estimated)
Optionable	Optionable	Optionable	Not Optionable	Optionable	Optionable

Source	Headline
	Amneal Pharmaceuticals Inc. (NYSE:AMRX): The most interesting shares today marketingsentinel.com - May 10 at 3:28 PM
	RBC Capital Mkts slashes price target on Amneal Pharmaceuticals Inc. [AMRX] – find out why. dbtnews.com - May 10 at 3:28 PM
	Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q1 2021 Results - Earnings Call Transcript seekingalpha.com - May 8 at 6:40 PM
	Amneal Pharmaceuticals, Inc. (AMRX) Q1 2021 Earnings Call Transcript fool.com - May 7 at 6:19 PM
	Amneal Pharmaceuticals (NYSE:AMRX) Shares Down 7.4% americanbankingnews.com - May 7 at 3:32 PM
	Amneal Reports First Quarter 2021 Financial Results uk.finance.yahoo.com - May 7 at 9:44 AM
	Amneal: Q1 Earnings Snapshot sfgate.com - May 7 at 9:44 AM
	Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates finance.yahoo.com - May 7 at 9:44 AM
	Amneal Pharmaceuticals (NYSE:AMRX) Stock Rating Upgraded by TheStreet marketbeat.com - May 6 at 7:15 AM
	Amneal Pharmaceuticals A earnings preview: what Wall Street is expecting markets.businessinsider.com - May 5 at 10:36 PM
	5.26% jump drives Amneal Pharmaceuticals Inc. (AMRX) into becoming a top stock for investors marketingsentinel.com - May 4 at 10:36 AM
	Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Short Interest Up 29.4% in April americanbankingnews.com - May 3 at 7:18 AM
	Earnings Preview: Amneal Pharmaceuticals (AMRX) Q1 Earnings Expected to Decline finance.yahoo.com - April 30 at 5:51 PM
	Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Surged 7.98% In 6 Months – Here’s What Happens Next marketingsentinel.com - April 24 at 1:40 PM
	What do Wall Street analysts think about Amneal Pharmaceuticals, Inc. (NYSE:AMRX) stock? stocksregister.com - April 18 at 9:26 AM
	Amneal to Report First Quarter 2021 Results on May 7, 2021 finance.yahoo.com - April 15 at 8:31 AM
	Is Now The Right Time To Buy Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Stock? stocksregister.com - April 13 at 9:06 AM
	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Amneal Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors finance.yahoo.com - April 12 at 8:53 AM
	Is Amneal Pharmaceuticals, Inc.'s (NYSE:AMRX) 19% ROE Strong Compared To Its Industry? finance.yahoo.com - April 9 at 7:25 AM
	Amneal Pharmaceuticals (NYSE:AMRX) Shareholders Have Enjoyed An Impressive 121% Share Price Gain nasdaq.com - April 7 at 9:18 AM
	Amneal Pharma buys Kashiv Specialty Pharma medicaldialogues.in - April 6 at 8:32 AM
	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Amneal Pharmaceuticals, Inc. (AMRX) finance.yahoo.com - March 31 at 2:48 PM
	If You’re Not Bullish on Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Now, You’ll Kick Yourself Later stocksregister.com - March 29 at 10:09 AM
	Amneal Posts Better-Than-Expected Q4 Results; Upbeat 2021 Revenue Outlook finance.yahoo.com - March 1 at 1:29 PM
	Analysts Have Conflicting Sentiments on These Healthcare Companies: BridgeBio Pharma (BBIO), Amneal Pharmaceuticals (AMRX) and VBI Vaccines (VBIV) smarteranalyst.com - February 26 at 10:44 PM
	Amneal Pharmaceuticals, Inc. (AMRX) Q4 2020 Earnings Call Transcript fool.com - February 26 at 6:35 PM

Date	Company	Brokerage	Action
12/2/2020	Heron Therapeutics	SVB Leerink	Boost Price Target
9/8/2020	Heron Therapeutics	Stifel Nicolaus	Reiterated Rating
8/6/2020	Heron Therapeutics	Northland Securities	Initiated Coverage
5/26/2020	Heron Therapeutics	Guggenheim	Initiated Coverage
5/18/2020	Heron Therapeutics	FIX	Initiated Coverage
4/15/2020	Heron Therapeutics	Needham & Company LLC	Reiterated Rating
2/20/2020	Heron Therapeutics	Cantor Fitzgerald	Reiterated Rating
1/15/2020	Heron Therapeutics	Cowen	Reiterated Rating
10/3/2019	Heron Therapeutics	JMP Securities	Lower Price Target
8/13/2019	Heron Therapeutics	Evercore ISI	Reiterated Rating
4/19/2021	Supernus Pharmaceuticals	Jefferies Financial Group	Upgrade
2/3/2021	Supernus Pharmaceuticals	Piper Sandler	Boost Price Target
11/8/2019	Supernus Pharmaceuticals	Berenberg Bank	Downgrade
8/7/2019	Supernus Pharmaceuticals	Mizuho	Reiterated Rating
3/4/2019	Supernus Pharmaceuticals	B. Riley	Set Price Target
1/16/2019	Supernus Pharmaceuticals	Piper Jaffray Companies	Set Price Target
5/10/2021	ADC Therapeutics	Morgan Stanley	Lower Price Target
5/3/2021	ADC Therapeutics	HC Wainwright	Boost Price Target
6/9/2020	ADC Therapeutics	Bank of America	Initiated Coverage
5/7/2021	Aurinia Pharmaceuticals	Royal Bank of Canada	Lower Price Target
5/7/2021	Aurinia Pharmaceuticals	Oppenheimer	Reiterated Rating
11/3/2020	Aurinia Pharmaceuticals	Bloom Burton	Downgrade
6/16/2020	Aurinia Pharmaceuticals	BTIG Research	Initiated Coverage
3/15/2021	Amneal Pharmaceuticals	The Goldman Sachs Group	Upgrade
3/1/2021	Amneal Pharmaceuticals	Barclays	Boost Price Target
5/13/2020	Amneal Pharmaceuticals	SunTrust Banks	Boost Price Target
12/12/2019	Amneal Pharmaceuticals	Raymond James	Downgrade
11/12/2019	Amneal Pharmaceuticals	JPMorgan Chase & Co.	Downgrade
8/6/2019	Amneal Pharmaceuticals	BMO Capital Markets	Lower Price Target

(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources